NVO Mar 2025 155.000 call
| Previous close | 12.15 |
| Open | 12.68 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 155.00 |
| Expiry date | 2025-03-21 |
| Day's range | 12.15 - 12.68 |
| Contract range | N/A |
| Volume | |
| Open interest | 229 |
Globe NewswireNovo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 24 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiat
The TelegraphNestle to sell supplements that tackle ‘Ozempic face’
Nestlé is to target “Ozempic face” by selling dietary supplements to counteract the effects of weight-loss drugs.
GlobeNewswireNovo Nordisk A/S: Mim8 demonstrated superior reductions in annualised bleeding rate (ABR) compared to on-demand and prior prophylaxis treatment in people with haemophilia A
FRONTIER2 data presented at ISTH 2024 showed that up to 95% of people, who had no prior prophylaxis treatment, experienced zero treated bleeds while on Mim8 Bagsværd, Denmark, 23 June 2024 – Novo Nordisk announced results from the phase 3 FRONTIER2 trial of 254 adults and adolescents aged 12 years and over with haemophilia A, with and without inhibitors. The trial assessed both once-weekly and once-monthly prophylactic treatment (regular treatment to prevent prolonged and spontaneous bleeding) w
